HTG Molecular Diagnostics Stock Forecast, Price & News

+0.27 (+5.53 %)
(As of 06/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume59,886 shs
Average Volume134,781 shs
Market Capitalization$32.31 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive HTGM News and Ratings via Email

Sign-up to receive the latest news and ratings for HTG Molecular Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

HTG Molecular Diagnostics logo

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG lung fusions assay; HTG EdgeSeq ALKPlus assay EU; HTG immune response panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.37 out of 5 stars

Medical Sector

788th out of 2,100 stocks

Analytical Instruments Industry

16th out of 32 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

HTG Molecular Diagnostics (NASDAQ:HTGM) Frequently Asked Questions

Is HTG Molecular Diagnostics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HTG Molecular Diagnostics stock.
View analyst ratings for HTG Molecular Diagnostics
or view top-rated stocks.

What stocks does MarketBeat like better than HTG Molecular Diagnostics?

Wall Street analysts have given HTG Molecular Diagnostics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but HTG Molecular Diagnostics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting HTG Molecular Diagnostics?

HTG Molecular Diagnostics saw a increase in short interest in May. As of May 28th, there was short interest totaling 224,700 shares, an increase of 33.7% from the May 13th total of 168,100 shares. Based on an average daily trading volume, of 101,900 shares, the short-interest ratio is presently 2.2 days. Currently, 3.9% of the company's stock are sold short.
View HTG Molecular Diagnostics' Short Interest

When is HTG Molecular Diagnostics' next earnings date?

HTG Molecular Diagnostics is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for HTG Molecular Diagnostics

How were HTG Molecular Diagnostics' earnings last quarter?

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) announced its earnings results on Thursday, May, 13th. The medical research company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.15. The medical research company earned $1.44 million during the quarter, compared to the consensus estimate of $1.40 million. HTG Molecular Diagnostics had a negative net margin of 261.44% and a negative trailing twelve-month return on equity of 120.05%.
View HTG Molecular Diagnostics' earnings history

How has HTG Molecular Diagnostics' stock price been impacted by Coronavirus?

HTG Molecular Diagnostics' stock was trading at $0.3942 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, HTGM stock has increased by 1,206.4% and is now trading at $5.15.
View which stocks have been most impacted by COVID-19

What guidance has HTG Molecular Diagnostics issued on next quarter's earnings?

HTG Molecular Diagnostics issued an update on its first quarter 2021 earnings guidance on Tuesday, May, 4th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $1.40 million-$1.40 million, compared to the consensus revenue estimate of $2.39 million.

What price target have analysts set for HTGM?

2 brokers have issued 12 month price objectives for HTG Molecular Diagnostics' stock. Their forecasts range from $9.00 to $10.00. On average, they anticipate HTG Molecular Diagnostics' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 84.5% from the stock's current price.
View analysts' price targets for HTG Molecular Diagnostics
or view top-rated stocks among Wall Street analysts.

Who are HTG Molecular Diagnostics' key executives?

HTG Molecular Diagnostics' management team includes the following people:
  • Mr. John L. Lubniewski, Pres, CEO & Director (Age 57, Pay $384.87k)
  • Mr. Shaun D. McMeans, Sr. VP of Fin. & Admin., CFO, Sec. and Treasurer (Age 59, Pay $321.37k)
  • Ms. Laura Lee Godlewski, VP of Fin. & Principal Accounting Officer (Age 41)
  • Dr. Maureen T. Cronin, Sr. VP & Chief Scientific Officer (Age 68)
  • Dr. Debra A. Gordon, Sr. VP & Chief Legal Counsel (Age 61)
  • Dr. Patrick C. Roche, Sr. VP of R&D (Age 68)
  • Mr. Byron T. Lawson, Sr. VP & Chief Commercial Officer (Age 46)
  • Laura Beggrow, Pres of Diagnostics

What is Tim (TJ) Johnson's approval rating as HTG Molecular Diagnostics' CEO?

11 employees have rated HTG Molecular Diagnostics CEO Tim (TJ) Johnson on Tim (TJ) Johnson has an approval rating of 47% among HTG Molecular Diagnostics' employees. This puts Tim (TJ) Johnson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of HTG Molecular Diagnostics' key competitors?

What other stocks do shareholders of HTG Molecular Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HTG Molecular Diagnostics investors own include Idera Pharmaceuticals (IDRA), Biocept (BIOC), Rigel Pharmaceuticals (RIGL), Heat Biologics (HTBX), MEI Pharma (MEIP), Zosano Pharma (ZSAN), Verastem (VSTM), Aurinia Pharmaceuticals (AUPH), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did HTG Molecular Diagnostics IPO?

(HTGM) raised $50 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 3,600,000 shares at $13.00-$15.00 per share. Leerink Partners served as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is HTG Molecular Diagnostics' stock symbol?

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

Who are HTG Molecular Diagnostics' major shareholders?

HTG Molecular Diagnostics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Cowen Prime Services LLC (8.43%), Samjo Capital LLC (6.92%), Blue Water Life Science Advisors LLC (2.40%), Renaissance Technologies LLC (2.23%), Worth Venture Partners LLC (0.88%) and Citadel Advisors LLC (0.30%).
View institutional ownership trends for HTG Molecular Diagnostics

Which institutional investors are buying HTG Molecular Diagnostics stock?

HTGM stock was bought by a variety of institutional investors in the last quarter, including Blue Water Life Science Advisors LLC, Cowen Prime Services LLC, Worth Venture Partners LLC, Samjo Capital LLC, Renaissance Technologies LLC, Citadel Advisors LLC, and Citadel Advisors LLC.
View insider buying and selling activity for HTG Molecular Diagnostics
or or view top insider-buying stocks.

How do I buy shares of HTG Molecular Diagnostics?

Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is HTG Molecular Diagnostics' stock price today?

One share of HTGM stock can currently be purchased for approximately $5.15.

How much money does HTG Molecular Diagnostics make?

HTG Molecular Diagnostics has a market capitalization of $32.31 million and generates $8.55 million in revenue each year. The medical research company earns $-20,870,000.00 in net income (profit) each year or ($4.42) on an earnings per share basis.

How many employees does HTG Molecular Diagnostics have?

HTG Molecular Diagnostics employs 83 workers across the globe.

What is HTG Molecular Diagnostics' official website?

The official website for HTG Molecular Diagnostics is

Where are HTG Molecular Diagnostics' headquarters?

HTG Molecular Diagnostics is headquartered at 3430 E. GLOBAL LOOP, TUCSON AZ, 85706.

How can I contact HTG Molecular Diagnostics?

HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615.

This page was last updated on 6/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.